Companies /Healthcare

Nektar Therapeutics

NASDAQ: NKTR Biotechnology
$72.74
▲ $0.99 (+1.38%) today
Markets closed · 2:29am ET
Today · % change

24/7 Wall St. View

Fundamentals

Market Cap
$2.4B
Profit Margin
-287.8%
Revenue (TTM)
$54.6M
EPS (TTM)
$-6.15
52-Week Range
$32 – $109
Street Target
$144.40

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical firm based in San Francisco, focusing on creating innovative medicines in immunotherapy. The company is working on treatments for a range of conditions, including systemic lupus erythematosus, ulcerative colitis, atopic dermatitis, psoriasis, non-Hodgkin’s lymphoma, multiple myeloma, and various cancers. With a strong commitment to advancing healthcare, Nektar Therapeutics collaborates with leading pharmaceutical companies worldwide to bring new therapies to patients in need.

NKTR Coverage